CD371-YSNVZ-IL18 CAR T cells
/ Memorial Sloan-Kettering Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 23, 2026
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Aug 2026 ➔ Dec 2026
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD37 • FLT3 • IDH1 • IDH2 • IL18
August 30, 2023
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center
CAR T-Cell Therapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD37 • FLT3 • IDH1 • IDH2 • IL18
1 to 2
Of
2
Go to page
1